Full US approval of Gilead’s Tecartus was the only positive decision last month.
ApexOnco Front Page
Recent articles
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA mutants, as well as wild types.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
2026’s first big oncology buyout is here.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Darovasertib data are promised for the last week of March.
The company buys in a PI3Kα and mTOR combo.
